Published in Arthritis Rheum on June 01, 2003
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med (2004) 3.56
Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med (2005) 3.04
Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med (2005) 2.39
Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood (2010) 2.17
Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow. J Exp Med (2005) 1.86
Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med (2006) 1.80
Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis (2007) 1.65
Roles of B cells in rheumatoid arthritis. Arthritis Res Ther (2003) 1.57
Primary Sjögren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis (2004) 1.54
Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Nat Rev Endocrinol (2010) 1.39
Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis (2005) 1.33
Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol (2006) 1.24
CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.24
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther (2011) 1.23
B-lymphocyte depletion ameliorates Sjögren's syndrome in Id3 knockout mice. Immunology (2007) 1.22
Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood (2014) 1.22
Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci U S A (2005) 1.15
T cell-dependent survival of CD20+ and CD20- plasma cells in human secondary lymphoid tissue. Blood (2007) 1.11
Rituximab for treatment-resistant extensive Wegener's granulomatosis--additive effects of a maintenance treatment with leflunomide. Clin Rheumatol (2007) 1.08
Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Ther Adv Neurol Disord (2011) 1.05
A perspective on B-cell-targeting therapy for SLE. Mod Rheumatol (2009) 1.03
Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma. P T (2010) 1.03
Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. Arthritis Res Ther (2005) 0.97
Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord (2011) 0.96
Neuromyelitis Optica. Curr Treat Options Neurol (2005) 0.93
Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res Ther (2011) 0.93
The complex role of Fcgamma receptors in the pathology of arthritis. Springer Semin Immunopathol (2006) 0.91
Rituximab in life threatening antisynthetase syndrome. Rheumatol Int (2009) 0.90
Acute and probable chronic Q fever during anti-TNFα and anti B-cell immunotherapy: a case report. BMC Infect Dis (2014) 0.90
Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis (2005) 0.88
Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature. Clin Rheumatol (2010) 0.87
Autoantibodies to posttranslational modifications in rheumatoid arthritis. Mediators Inflamm (2014) 0.86
Rituximab-based treatment, HCV replication, and hepatic flares. Clin Dev Immunol (2012) 0.84
Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome. Ther Adv Musculoskelet Dis (2015) 0.84
Cell therapy for autoimmune diseases: does it have a future? Ann Rheum Dis (2004) 0.83
Long lasting remission by rituximab in a patient with primary cold agglutinin autoimmune haemolytic anaemia. Wien Klin Wochenschr (2011) 0.81
Targeting B cells with biologics in systemic lupus erythematosus. Expert Opin Biol Ther (2010) 0.80
Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria. J Clin Aesthet Dermatol (2013) 0.79
Immune Thrombocytopenic Purpura and Gastritis by H. pylori Associated With Type 1 Diabetes Mellitus. Cureus (2016) 0.77
[Autoantibodies and antibody-secreting cells]. Z Rheumatol (2005) 0.76
Design of smart HPMA copolymer-based nanomedicines. J Control Release (2015) 0.76
Management of antiphospholipid syndrome. Ther Adv Musculoskelet Dis (2010) 0.76
Good outcome after rituximab treatment for a mixed warm and cold autoimmune haemolytic anaemia. BMJ Case Rep (2009) 0.76
Successful treatment of relapsing autoimmune pancreatitis in primary Sjögren's syndrome with rituximab: report of a case and review of the literature. Rheumatol Int (2009) 0.75
Rituximab therapy in steroid-resistant severe hypothyroid Grave's ophthalmopathy. Indian J Endocrinol Metab (2013) 0.75
Successful cataract surgery in a patient with refractory Wegener's granulomatosis effectively treated with rituximab: A case report. Saudi J Ophthalmol (2016) 0.75
The Function of FK506-Binding Protein 13 in Protein Quality Control Protects Plasma Cells from Endoplasmic Reticulum Stress-Associated Apoptosis. Front Immunol (2017) 0.75
B cell signalling as therapeutic target. Ann Rheum Dis (2004) 0.75
NFATc2 (NFAT1) assists BCR-mediated anergy in anti-insulin B cells. Mol Immunol (2014) 0.75
Forty-year-old diabetic lady with tightness in lower limbs. Ann Indian Acad Neurol (2012) 0.75
B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab. Biologics (2012) 0.75
Factors affecting rheumatoid arthritis patients' decisions to participate in clinical trials. J Rheumatol (2005) 2.15